Deutsche Diabetes Forschungsgesellschaft e.V.

Verified siteinfo

Germany Auf'm Hennekamp 65, Nordrhein-Westfalen, 40225 Duesseldorf, Germany

5 trials recruiting
Type 2 diabetes mellitus · Cardiovascular disorder · Chronic kidney disease
Adult patients

About Specializations

Deutsche Diabetes Forschungsgesellschaft e.V. in Duesseldorf, Germany specialises in clinical trials of conditions such as Type 2 diabetes mellitus, Cardiovascular disorder, Chronic kidney disease, Diabetic neuropathy, and other specialisations. This site conducts important research.

Main research areas of the site

Nephrology and Endocrinology

The medical center is at the forefront of research in nephrology and endocrinology, focusing on innovative approaches to manage and treat conditions such as chronic kidney disease and prediabetes. The center's research aims to explore the potential of SGLT2 inhibitors in conjunction with lifestyle interventions to mitigate the risk of complications in patients with early-stage kidney disease.

Chronic Kidney Disease Management
Prediabetes Intervention
SGLT2 Inhibition Therapy

By integrating clinical trials with lifestyle modifications, the center is pioneering new therapeutic strategies that could significantly improve patient outcomes and reduce the progression of kidney damage.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Auf'm Hennekamp 65, Nordrhein-Westfalen40225 DuesseldorfGermany

Open in maps ↗

Recruiting now: 5 trials
Conditions studied: 6
Partner status: Verified site

More sites in Duesseldorf Germany

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

5 clinical trials

Cardiovascular disorder+2

Recruiting

Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

Registered drug

Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:BI 690517
Sponsor:Boehringer Ingelheim Espana S.A.

Contact Research Centre

Metabolic dysfunction-associated liver disease

Recruiting

N1T-MC-MALO: A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes); N1T-MC-TZ01 Tirzepatide in participants with high-risk MASLD; N1T-MC-RT01 Retatrutide in participants with high-risk MASLD

Investigational

N1T-MC-MALO: A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes); N1T-MC-TZ01 Tirzepatide in participants with high-risk MASLD; N1T-MC-RT01 Retatrutide in participants with high-risk MASLD

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:LY3437943 sodium
Sponsor:Eli Lilly & Co.

Contact Research Centre

Diabetic neuropathy

Recruiting

A study testing capsaicin patches compared to placebo for patients with painful diabetic nerve damage to assess effects on nerve symptoms and nerve fibers

Registered drug